Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA HCT vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (to lower blood pressure, either as initial therapy or in patients not adequately controlled on monotherapy)
Hypertension
Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Aliskiren: terminal half-life 24-31 hours (accumulation supports once-daily dosing). Hydrochlorothiazide: 6-15 hours (correlates with duration of action).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Aliskiren is primarily metabolized by CYP3A4; Hydrochlorothiazide is not metabolized and excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Aliskiren: 78-91% unchanged in feces via biliary excretion, <2.4% in urine. Hydrochlorothiazide: ≥95% renal, 50-75% unchanged.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Aliskiren: 47-51% (albumin). Hydrochlorothiazide: 40-68% (albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Aliskiren: 0.65-2.3 L/kg (extensive tissue distribution due to lipophilicity). Hydrochlorothiazide: 3-7 L/kg (distributes into erythrocytes).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Aliskiren: 2-5% oral (1.6-2.8% at 300 mg). Hydrochlorothiazide: 65-70% oral.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated in patients with GFR <30 m L/min/1.73m2. For GFR 30-59 m L/min/1.73m2: no dose adjustment required, but monitor serum potassium and creatinine. Discontinue if progressive oliguria or acute renal failure occurs.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: use with caution; no specific dose guidelines.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Safety and efficacy not established in pediatric patients less than 18 years of age.
Not established; avoid use in children.
Elderly patients may be more sensitive to hypotension and electrolyte imbalances. Start at the lowest dose (150/12.5 mg) and titrate cautiously. Monitor renal function and electrolytes regularly.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Avoid use in pregnancy (especially 2nd and 3rd trimesters) due to fetal toxicity; discontinue immediately if pregnancy occurs.,Not recommended with ACE inhibitors or ARBs in patients with diabetes or renal impairment (Cr Cl < 60 m L/min) due to increased risk of renal dysfunction, hyperkalemia, and hypotension.,Symptomatic hypotension may occur, especially in volume-depleted patients; correct volume depletion before use.,Electrolyte imbalances: monitor serum potassium (risk of hyperkalemia), sodium, and magnesium; hydrochlorothiazide may cause hypokalemia, hyponatremia, and hypomagnesemia.,Renal impairment: monitor renal function; may cause acute renal failure; contraindicated with Cr Cl < 30 m L/min for hydrochlorothiazide component.,Angioedema may occur; discontinue if develops.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Pregnancy (risk of fetal harm),Anuria (due to hydrochlorothiazide component),Concomitant use with ACE inhibitors or ARBs in patients with diabetes mellitus or moderate-to-severe renal impairment (Cr Cl < 60 m L/min),Hypersensitivity to any component (including sulfonamide-derived drugs for hydrochlorothiazide)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and potassium-containing salt substitutes. Limit sodium intake to assist antihypertensive effect. Grapefruit juice may reduce aliskiren absorption; avoid concurrent consumption.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossification defects. Second and third trimesters: Exposure is associated with fetal hypotension, anuria, renal failure, oligohydramnios, skull hypoplasia, and death. Hydrochlorothiazide: Crosses the placenta; risk of electrolyte disturbances, jaundice, and thrombocytopenia in the newborn. Generally avoid in pregnancy, especially second and third trimesters.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Aliskiren: Not known if excreted in human milk. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio not reported. Use with caution, monitor infant for dehydration, electrolyte imbalance. Consider alternatives if possible.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Avoid use during pregnancy. If exposure occurs, discontinue as soon as possible. No recommended dose adjustments; alternative agents are preferred. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, renal clearance) may reduce drug efficacy, but no specific dose adjustment studies exist for this combination.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Tekturna HCT is a fixed-dose combination of aliskiren (renin inhibitor) and hydrochlorothiazide (thiazide diuretic). Avoid use in pregnancy (category D). Monitor renal function and serum electrolytes, especially potassium and sodium, as aliskiren can increase potassium and HCTZ can cause hypokalemia. Contraindicated with concomitant use of ARBs or ACE inhibitors in patients with diabetes or renal impairment (e GFR <60 m L/min/1.73 m²). Assess for hypotension, especially in volume-depleted patients. Max antihypertensive effect may take 2-4 weeks.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid potassium supplements, salt substitutes, or high-potassium foods without consulting your doctor.,Take exactly as prescribed; do not skip doses or double up.,May cause dizziness; avoid driving until you know how the medication affects you.,Drink adequate fluids to prevent dehydration, especially in hot weather or with exercise.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion.,Avoid alcohol as it may increase blood pressure-lowering effects and dizziness.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA HCT vs ALDORIL 25, answered by our medical review team.
TEKTURNA HCT is a Antihypertensive combination that works by Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA HCT and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA HCT is: Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA HCT and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA HCT is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossificati. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.